Shufeng Xingbi Therapy Alters Immune and Microbiome Landscapes in Allergic Rhinitis: Evidence from a Rat Model

Study Background and Research Question

Allergic rhinitis (AR) is a non-infectious, IgE-mediated chronic inflammatory disorder of the nasal mucosa, affecting over 10% of the global population and contributing to considerable morbidity (source: paper). Pathogenesis centers on an imbalance between Th1 and Th2 immune responses, with excessive Th2 activity promoting inflammation and allergic symptoms. While conventional therapies—such as glucocorticoids and antihistamines—provide symptomatic relief, they often result in systemic side effects, particularly in pediatric populations. An emerging research focus considers the role of the gut microbiota in immune regulation, consistent with the “hygiene hypothesis” linking microbial exposures to the development of atopic diseases. In this context, Shufeng Xingbi Therapy (SFXBT), a modality rooted in Traditional Chinese Medicine, has shown clinical promise for AR, but its mechanistic underpinnings in modulating immune balance and microbiota remain insufficiently understood.

Key Innovation from the Reference Study

The referenced study provides a controlled, multi-modal investigation of SFXBT’s capacity to correct Th1/Th2 immune imbalance and reshape the intestinal microbiome in an ovalbumin (OVA)-induced rat model of AR. Critically, it integrates immunological, histological, and microbiological endpoints, representing one of the first preclinical reports to connect SFXBT’s effects on nasal inflammation with gut microbial composition and key immune signaling pathways (source: paper).

Methods and Experimental Design Insights

Thirty-two male Sprague Dawley rats were randomized into four groups: control, OVA-induced AR, antibiotic + SFXBT, and acetic acid + SFXBT. Allergic rhinitis was established using ovalbumin sensitization and challenge. SFXBT was administered both orally (recipe) and intranasally (gel drops), paralleling clinical regimens. The study employed a comprehensive suite of assays:

• Behavioral scoring: Quantified AR symptom severity.
• Histopathology: Hematoxylin & eosin staining assessed nasal mucosa integrity.
• Microbiota profiling: 16S rDNA sequencing characterized fecal microbial shifts.
• Immunology: Serum IgE, IL-4, and short-chain fatty acids (SCFAs) quantified by ELISA; mRNA (STAT5, STAT6, GATA3) measured by RT-qPCR; and protein levels (IL-4, STAT5, STAT6, GATA3) by Western blot.

This integrative approach facilitated the mapping of SFXBT’s multi-level effects on both local nasal immunity and systemic (gut) microbial ecology.

Protocol Parameters

• AR model induction | OVA 10% solution, intranasal instillation | Rat AR model | Standardized induction of allergic phenotype | paper
• SFXBT administration | Oral + intranasal, dose per established TCM protocol | AR rats | Mimics clinical application, allows systemic and local effects | paper
• Microbiota analysis | 16S rDNA sequencing, Illumina platform | Fecal samples | High-resolution genus- and phylum-level profiling | paper
• Antibiotic pre-treatment (for flora depletion) | Vancomycin or cocktail, typical dose 50-100 mg/kg/day (workflow_recommendation) | Microbiota research models | Selective depletion of Gram-positive flora to study immune-microbiota interactions | workflow_recommendation
• Vancomycin solubility for in vivo studies | ≥97.2 mg/mL in DMSO | Preclinical models | Ensures high dosing accuracy and compound stability | product_spec

Core Findings and Why They Matter

SFXBT-treated AR rats exhibited significant reduction in behavioral AR scores and alleviation of nasal mucosa pathology compared to the OVA group (source: paper). On the immunological front, SFXBT groups showed decreased serum IgE and IL-4 levels, suggesting a shift away from Th2-dominant responses. Notably, SFXBT also downregulated mRNA and protein expression of STAT5, STAT6, and GATA3—transcriptional regulators associated with Th2 polarization—indicating suppression of the allergic inflammatory cascade. Concomitant with immunological shifts, SFXBT modulated gut microbiota composition. At the phylum level, Firmicutes increased and Bacteroidetes decreased, while genus-level analysis revealed elevations in Lactobacillus, Romboutsia, Allobaculum, and Dubosiella. This rebalancing coincided with elevated SCFA levels, metabolites known to influence immune tolerance and inflammation. The findings support the hypothesis that SFXBT’s benefit extends beyond symptom control to mechanistically relevant adjustments in gut-immune signaling axes.

Comparison with Existing Internal Articles

Several internal resources discuss the use of antibacterial agents—particularly glycopeptide antibiotics such as Vancomycin—in dissecting microbiota-immune interactions:

• In "Vancomycin: A Precision Glycopeptide Antibiotic Shaping Translational Microbiota Research", Vancomycin is characterized as a high-affinity peptidoglycan precursor binding agent, used to deplete Gram-positive bacteria and manipulate microbial communities in preclinical models. This approach mirrors the antibiotic pre-treatment arm of the current study, which clarifies the role of gut flora in AR pathogenesis and immune regulation.
• The guide "Vancomycin: Glycopeptide Antibiotic for Advanced MRSA & Microbiota Research" provides practical protocols for Vancomycin-based flora modulation, supporting reproducibility in microbiota-targeted research.
• Additionally, "Vancomycin in Experimental Microbiota Engineering and Immune Modulation" explores how glycopeptide antibiotics facilitate the study of host-microbe-immune crosstalk, directly aligning with the mechanistic focus of the SFXBT paper.

The key distinction in the present study lies in its dual focus: not only does it use antibiotic-driven microbiota disruption to clarify immune mechanisms, but it also tests a therapeutic intervention (SFXBT) capable of restoring both microbial and immunological balance.

Limitations and Transferability

Despite methodological rigor, the study’s translational reach is bounded by several factors. First, as an animal model study, extrapolation to human AR must be cautious. Second, the antibiotic pre-treatment employed does not fully recapitulate the complexity of clinical microbiota perturbations. Third, while changes in immune markers and microbiota composition are clearly demonstrated, causal pathways remain to be resolved, and the specific microbial taxa most critical for the observed immune modulation are not fully delineated. Finally, the SFXBT formulation—rooted in Traditional Chinese Medicine—may exhibit variable pharmacodynamics across species (source: paper).

Research Support Resources

For researchers seeking to model microbiota-immune interactions or reproduce antibiotic-driven flora depletion protocols, high-purity tools are essential. Vancomycin (SKU C6417) is a well-characterized glycopeptide antibiotic for selective depletion of Gram-positive bacteria, enabling precise manipulation of gut flora in preclinical immunology and bacterial resistance studies—including the type of workflow illustrated in this AR model (source: internal_article). Supplied by APExBIO with validated purity and solubility characteristics, Vancomycin supports reproducible experimental design in both microbiota engineering and antibacterial agent for MRSA research. Researchers are advised to consult detailed product specifications and literature for dosing and solubility guidance when implementing such protocols.